
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
A 2-1/2-year-old girl's adenopathy has not subsided five days after initiation of antibiotic therapy with amoxicillin and clavulanate potassium (Augmentin). And lately, she seems to be having "a lot" of nosebleeds.






